| 3.95 0.38 (10.64%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.41 | 1-year : | 6.32 |
| Resists | First : | 4.63 | Second : | 5.41 |
| Pivot price | 3.46  |
|||
| Supports | First : | 3.27 | Second : | 2.44 |
| MAs | MA(5) : | 3.22 |
MA(20) : | 3.63 |
| MA(100) : | 5.42 |
MA(250) : | 7.7 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 57.1 |
D(3) : | 37.5 |
| RSI | RSI(14): 54.3 |
|||
| 52-week | High : | 13.14 | Low : | 2.44 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SPRY ] has closed below upper band by 24.4%. Bollinger Bands are 3.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.13 - 4.14 | 4.14 - 4.16 |
| Low: | 3.53 - 3.55 | 3.55 - 3.56 |
| Close: | 3.92 - 3.95 | 3.95 - 3.97 |
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
Thu, 12 Nov 2026
ARS Pharmaceuticals, Inc. (SPRY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Fri, 06 Nov 2026
ARS Pharmaceuticals Inc (SPRY) Q3 2026 Earnings Call Highlights: neffy Market Share Tops 5% as ... - Yahoo Finance
Thu, 05 Nov 2026
ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Wed, 04 Nov 2026
Earnings To Watch: ARS Pharmaceuticals Inc (SPRY) Q3 2026 -- GF Value Sees 829% Upside - Yahoo Finance
Wed, 23 Sep 2026
SPRY Investor Alert: ARS Pharmaceuticals Inc. Securities Class Action Notice - Contact Levi & Korsinsky - PR Newswire
Thu, 13 Aug 2026
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 101 (M) |
| Shares Float | 49 (M) |
| Held by Insiders | 16.1 (%) |
| Held by Institutions | 91.9 (%) |
| Shares Short | 19,820 (K) |
| Shares Short P.Month | 23,070 (K) |
| EPS | -2.01 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.12 |
| Profit Margin | -163.7 % |
| Operating Margin | -90.7 % |
| Return on Assets (ttm) | -39.5 % |
| Return on Equity (ttm) | -294.6 % |
| Qtrly Rev. Growth | 16 % |
| Gross Profit (p.s.) | 0.73 |
| Sales Per Share | 1.21 |
| EBITDA (p.s.) | -1.95 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -183 (M) |
| Levered Free Cash Flow | -113 (M) |
| PE Ratio | -1.97 |
| PEG Ratio | 0 |
| Price to Book value | -32.92 |
| Price to Sales | 3.25 |
| Price to Cash Flow | -2.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|